A nurse is caring for a client who has osteoporosis and a new prescription for raloxifene. Which of the following should the nurse assess prior to initiating therapy?

Choice A rationale Raloxifene's mechanism of action involves selective estrogen receptor modulation, which primarily affects bone density and cardiovascular health. It does not have a direct or clinically significant impact on thyroid function. Therefore, assessing thyroid status before initiating therapy is not a standard or necessary precaution. Choice B rationale Raloxifene is classified as a pregnancy category X medication. It poses a significant risk of harm to a developing fetus and is contraindicated in women who are pregnant or may become pregnant. Therefore, it is essential to assess the client's pregnancy status to prevent fetal exposure to the drug's teratogenic effects. Choice C rationale There is no known direct link between raloxifene therapy and a family history of colon cancer. While raloxifene has been studied for its effects on various cancers, it is not a primary risk factor for colon cancer. Therefore, assessing this specific family history is not a required pre-treatment assessment for this medication. Choice D rationale A complete blood count (CBC) is not a required pre-assessment for raloxifene therapy. While raloxifene can increase the risk of thromboembolism, this is not reflected in a standard CBC. The medication does not typically affect white blood cells, red blood cells, or platelets in a way that necessitates pre-treatment monitoring via this test.